Intervention

aspirin

ClinicalTrials.gov intervention label

Clinical trials11

Recruiting0

Common conditions16

Lead sponsors shown11

Clinical trials

11 shown

Role of Inflammatory Mediators in AERDNCT02824523 · 2016-07-01

Efficiency Study of Aspirin to Prevent the Occurrence of Prostate CancerNCT02757365 · 2014-04-01

The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory DiseasesNCT01867281 · 2013-06-01

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast CancerNCT01431053 · 2011-07-01

Chronotherapy with Low-dose Aspirin for Primary PreventionNCT00725127 · 2008-10-01

ACTIVE_NOT_RECRUITING

Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic PatientsNCT00812032 · 2008-01-01

Nephropathy In Type 2 Diabetes and Cardio-renal EventsNCT00535925 · 2005-10-01

Retinal Blood Flow and Microthrombi in Type 1 DiabetesNCT00406991 · 2003-06-01

Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus PatientsNCT00427271 · 2003-03-01

Secondary Prevention of Small Subcortical Strokes TrialNCT00059306 · 2003-02-01

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) TrialNCT00041938 · 2002-10-01

Common conditions

Asthma, Aspirin-Induced2 Breast Neoplasms1 Cerebrovascular Accident1 Diabetes1 Diabetes Mellitus1 Diabetic Nephropathy1 Diabetic Retinopathy1 Heart Disease1 Hypertension1 Ischemic Heart Disease1 Microalbuminuria1 Myocardial Infarction1 Prostate Cancer1 Stroke1 Type 2 Diabetes1 Type 2 Diabetes Mellitus1

Leading sponsors

Brigham and Women's Hospital1 Chinese Academy of Medical Sciences1 Columbia University1 Hospital de Clinicas de Porto Alegre1 Karolinska Institutet1 Schepens Eye Research Institute1 Tehran University of Medical Sciences1 University of British Columbia1 University of Campania Luigi Vanvitelli1 University of Vigo1 West China Hospital1

Trial status mix

COMPLETED7

UNKNOWN3

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE46

PHASE22

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.